🫀 ECG Analysis — Kya Problem Hai?

Machine ke Conclusions (ECG ke neeche likha hua):

1. Severity: Left Axis Deviation — Dil ki electrical axis left side shift ho gayi hai
2. 1° AV Block — SA node se AV node tak signal thoda slow ja raha hai (PR interval badha hua)
3. ST Depression — Heart ke muscles ko poora oxygen nahi mil raha (ischemia ka sign)
4. Possible Anterolateral Myocardial Ischemia — Dil ke aage aur side wale hisse mein blood supply kam ho sakti hai
5. High Lateral ST Depression — aVL aur high lateral leads mein ST neecha gira hua
6. I, aVL, V6 — Abnormal T Wave — In leads mein T wave ulti ya flat hai

Kya Matlab Hai Saral Bhasha Mein?

⚠️ Ye ECG Serious Hai!

Machine ne khud likha hai: "Report need physician confirm"

✅ Turant Kya Karna Chahiye:

1. Abhi doctor/cardiologist ko dikhao — ye ECG urgent attention maangta hai
2. Troponin blood test karwao — confirm karta hai dil ka damage hua hai ya nahi
3. Echocardiogram bhi recommend kiya ja sakta hai
4. Agar seene mein dard, saans phoolna, paseena, ghabhrahat ho — emergency hospital jao

⚕️ Disclaimer: Ye AI analysis hai. Ye ECG ki machine interpretation + mere observations pe based hai. Kisi qualified cardiologist se zaroor milwao — final diagnosis wahi karenge.

NSTEMI: Latest Guidelines (2025)

ACS Spectrum — Where NSTEMI Fits

From Harrison's 22E (2025), based on ESC 2023 ACS Guidelines

1. DIAGNOSIS

Clinical Presentation

• New onset within prior 2 weeks
• Crescendo pattern (more severe/frequent than before)
• Occurring at rest

ECG Findings

• ST depression ≥0.5 mm in ≥2 contiguous leads → most specific for NSTEMI ischemia (seen in ~1/3 of patients)
• New T-wave inversions ≥0.3 mV → significant
• No ST elevation required — ECG changes are NOT required to confirm NSTE-ACS diagnosis
• Serial ECGs are mandatory when initial ECG is nondiagnostic

Biomarkers (Cornerstone of Diagnosis)

• High-sensitivity cardiac Troponin (hs-cTn) is the recommended biomarker (Class I)
• NSTEMI = troponin rise/fall above 99th percentile + ischemic symptoms/ECG changes
• 0/1h or 0/2h rapid rule-out/rule-in pathways using hs-cTn are now standard (2025 ESC/ACC)
• CK-MB is no longer recommended for initial diagnosis

Risk Stratification (Mandatory)

2. MANAGEMENT

A. Anti-Ischemic Therapy (Immediate)

B. Antithrombotic Therapy (Two Pillars)

• Aspirin 150–325 mg loading → 75–100 mg/day maintenance (Class I)
• DAPT (Dual Antiplatelet Therapy): Add P2Y₁₂ inhibitor (Class I)
  • Ticagrelor 180 mg load → 90 mg BD (preferred; superior to clopidogrel — reduces CV death + MI)
  • Prasugrel 60 mg load → 10 mg/day (only post-angiography when PCI planned; avoid if prior stroke/TIA)
  • Clopidogrel 300–600 mg load → 75 mg/day (acceptable alternative, less potent)
• DAPT duration: Default 12 months post-ACS (Class I); if high bleeding risk → Ticagrelor monotherapy after 1 month post-PCI (Class I) — NEW 2025 recommendation

• UFH (unfractionated heparin) or Enoxaparin (LMWH) — Class I
• Fondaparinux — preferred in conservative strategy (lower bleeding)
• Bivalirudin — option during PCI

C. Statins (Early and Intensive)

• High-intensity statin: Atorvastatin 80 mg/day or Rosuvastatin 40 mg/day — initiated immediately (in-hospital)
• Target LDL-C: <55 mg/dL (1.4 mmol/L) with ≥50% reduction from baseline
• If target not achieved: add Ezetimibe 10 mg/day
• If still not at target: add PCSK9 inhibitor (Alirocumab/Evolocumab) — 2025 ESC/EAS update: combination therapy immediately at hospitalization, not stepwise after discharge

D. Invasive Strategy — When and How Soon?

• In NSTE-ACS with multivessel disease (MVD): PCI of non-culprit lesions (at index or staged) is now Class I recommendation to reduce MACE — upgraded from 2b in prior guidelines
• Elderly patients (≥80 years): Early invasive approach superior to conservative in stable octogenarians (SENIOR-NSTEMI data)

E. Secondary Prevention (Post-Discharge)

3. Key 2025 Updates vs Prior Guidelines

Sources

• Harrison's Principles of Internal Medicine 22E (2025), Chapter 285
• Goldman-Cecil Medicine, Chapter 57 — NSTE-ACS
• Rosen's Emergency Medicine — ACS section
• 2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS Guideline — replaces all prior US ACS guidelines
• 2025 ESC/EAS Focused Lipid Update — aggressive in-hospital LDL lowering
• CVIT 2026 PCI Consensus [PMID: 41749019]

⚕️ These guidelines are for clinical professionals. Individual patient management should be tailored by a treating cardiologist based on full clinical assessment.